ICICI Prudential Mutual Fund
When comparing, both lines start at 100. The fund's declared benchmark, a total-return index (dividends reinvested).
This is an IDCW (dividend) option: it pays cash out of its NAV, so returns computed from the NAV alone would understate what an investor earned. See the Growth option of the same plan for performance.
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. Shown from the Direct plan of this fund, which holds the same portfolio. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Equity & Equity Related Instruments | — | 99.93% | — | — |
| Listed / Awaiting Listing On Stock Exchanges | — | 99.93% | — | — |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 20.76% | — | 143.5 |
| Divi's Laboratories Ltd. | Healthcare | 11.88% | — | 83.0 |
| Cipla Ltd. | Healthcare | 7.83% | — | 35.1 |
| Laurus Labs Ltd. | Healthcare | 7.36% | — | 122.0 |
| Torrent Pharmaceuticals Ltd. | Healthcare | 7.34% | — | 77.7 |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 6.95% | — | 150.9 |
| Lupin Ltd. | Healthcare | 5.25% | — | 13.2 |
| Aurobindo Pharma Ltd. | Healthcare | 4.69% | — | 37.5 |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 3.69% | — | 316.1 |
| Alkem Laboratories Ltd. | Healthcare | 3.08% | — | 29.1 |
| Biocon Ltd. | Healthcare | 2.90% | — | 596.5 |
| Zydus Lifesciences Ltd. | Healthcare | 2.87% | — | 32.6 |
| IPCA Laboratories Ltd. | Healthcare | 2.71% | — | 39.8 |
| Mankind Pharma Ltd. | Healthcare | 2.70% | — | 46.9 |
| Gland Pharma Ltd. | Healthcare | 2.27% | — | 34.4 |
| Sai Life Sciences Ltd. | Healthcare | 1.99% | — | 89.9 |
| Wockhardt Ltd. | Healthcare | 1.54% | — | 94.2 |
| Ajanta Pharma Ltd. | Healthcare | 1.50% | — | 43.2 |
| Piramal Pharma Ltd. | Healthcare | 1.32% | — | 37.0 |
| Abbott India Ltd. | Healthcare | 1.31% | — | 34.5 |
| TREPS | — | 1.07% | — | — |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Oct 25 0.37% · Nov 25 0.37% · Dec 25 0.37% · Jan 26 0.37% · Feb 26 0.37% · Mar 26 0.38% · Apr 26 0.50% · May 26 0.38% · Jun 26 0.50% · Jul 26 0.48% · Aug 26 0.52% · Sep 26 0.51%
Nil
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
